Tryptophan Metabolism in Healthy Young Adults
1 other identifier
interventional
10
1 country
1
Brief Summary
Tryptophan is an essential amino acid needed for growth and bodily functions. It is used to make serotonin which is needed for the brain to develop and function properly. However, when the body is stressed, tryptophan is broken down into compounds that can cause harm to the brain. Premature babies who get nutrition through their vein \[i.e. total parenteral nutrition (TPN)\] can experience this type of stress. The amount of tryptophan in TPN solutions is much higher than what premature babies need and can produce too much harmful compounds. So, it is important to study the amount of these compounds made from tryptophan. But there are no methods available to study this. Therefore, the goal of this study is to develop a method to measure the compounds made from tryptophan breakdown in adults so that it can be used for preterm babies on TPN later.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable healthy
Started Jan 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 8, 2024
CompletedFirst Posted
Study publicly available on registry
August 13, 2024
CompletedStudy Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2025
CompletedMarch 30, 2026
May 1, 2025
7 months
August 8, 2024
March 25, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Fractional Synthesis Rate (FSR) of tryptophan metabolites
Enrichment of L-\[15N2\]tryptophan and its metabolites (15N2-L-kynurenine, 15N-kynurenic acid, 15N-quinolinic acid, 15N2-serotonin and 15N-5-hydroxyindole acetic acid) in plasma and urine following orally administered tracer, L-\[15N2\]tryptophan.
10 hours
Steady state
Time at which plasma and urine enrichment of L-\[15N2\]tryptophan reaches steady-state.
10 hours
Secondary Outcomes (2)
Partitioning of tryptophan metabolism
10 hours
Fractional synthesis rate (FSR)
10 hours
Study Arms (1)
Experimental: Tryptophan in healthy young adults (18-45 years)
EXPERIMENTALTryptophan intake levels, up to 5 levels, will be tested in a random order in all subjects
Interventions
There are 5 different tryptophan test intake levels ranging from 2, 3, 4.5, 6, 8 mg.kg-1.day.1
Eligibility Criteria
You may qualify if:
- Consent provided
- Aged 18 to 45 years old (inclusive)
- In good general health as evidenced by medical history, physical health and biochemistry
- Fasting blood glucose, hemoglobin A1c (HbA1c), urea, creatinine and CRP levels within normal ranges for age.
You may not qualify if:
- Presence of chronic disease and/or acute illness known to affect protein/amino acid metabolism (e.g. HIV, diabetes, cancer, liver or kidney disease, neurological conditions including depression and anxiety, hypo- / hyperthyroidism, inflammatory conditions,, anemia, acute cold or flu)
- Taking medications known to affect protein/AA metabolism (e.g. steroids, anti-inflammatory medications, acetaminophen, selective serotonin reuptake inhibitors (SSRI))
- Inability to tolerate the diet (i.e. allergy)
- Significant weight loss during the past month or consumption of weight reducing diets.
- Significant caffeine consumption (\>2 cups per day)
- Significant consumption of alcohol (\>1 drink per day i.e. 1 beer or ½ glass of wine).
- Unwilling to have blood drawn from a venous access or using a ventilated hood indirect calorimeter for the purposes of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Hospital for Sick Children
Toronto, Ontario, M5G 1E8, Canada
Study Officials
- PRINCIPAL INVESTIGATOR
Glenda Courtney-Martin, PhD, RD
The Hospital for Sick Children
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
August 8, 2024
First Posted
August 13, 2024
Study Start
January 1, 2025
Primary Completion
July 31, 2025
Study Completion
July 31, 2025
Last Updated
March 30, 2026
Record last verified: 2025-05